Eric Benson, MD
Internal Medicine · Post Falls, IDNPI 1639272644
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 1,123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,123 payments — averaging $17.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Amgen$2K
- AbbVie$2K
- Lilly USA, LLC$1K
- AstraZeneca$1K
- Teva Pharmaceuticals USA, Inc.$929
- plus $10K from 47 others
What the payments were for
- Food & beverage$19,02799%
- Education$1291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$19,157 in reported general payments places this provider in the 95th percentile of 289 internal medicine providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 140 | $115,780 |
| XareltoRivaroxaban | 129 | $111,042 |
| OzempicSemaglutide | 66 | $95,453 |
| MounjaroTirzepatide | 60 | $64,556 |
| EliquisApixaban | 70 | $45,039 |
| FarxigaDapagliflozin Propanediol | 41 | $32,470 |
| Aimovig AutoinjectorErenumab-Aooe | 44 | $31,939 |
| TrulicityDulaglutide | 14 | $26,702 |
| RexultiBrexpiprazole | 14 | $25,951 |
| Repatha SureclickEvolocumab | 20 | $22,033 |
| JardianceEmpagliflozin | 32 | $21,500 |
| MyrbetriqMirabegron | 20 | $18,124 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 30 | $17,996 |
| Breo ElliptaFluticasone/Vilanterol | 32 | $17,052 |
| NucyntaTapentadol Hcl | 12 | $16,930 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $2,777 | $153,361215 claims |
| Johnson & JohnsonXarelto | $922 | $111,042129 claims |
| Novo NordiskOzempic | $760 | $95,45366 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,168 | $91,25874 claims |
| PfizerEliquis | $846 | $45,03970 claims |
| AstraZenecaFarxiga | $1,085 | $32,47041 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $456 | $25,95114 claims |
| Collegium Pharmaceutical, Inc.Nucynta, Xtampza Er | $188 | $25,59525 claims |
| Boehringer IngelheimJardiance | $22 | $21,50032 claims |
| Astellas Pharma US IncMyrbetriq | $147 | $18,12420 claims |
| AbbVieQulipta, Synthroid | $1,534 | $15,89874 claims |
| BayerKerendia | $720 | $13,28115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 289 internal medicine providers in Idaho.
Other internal medicine in Post Falls
- Abby GardnerPost Falls$525
- Sherwin D'souzaPocatello$543K
- Diana DumitrascuEagle$143K
- Huiling QiBoise$62K
- Aditya SinghPocatello$37K
- Carolyn BridgesBoise$27K
- Susan WachterIdaho Falls$22K
- Ahmed MahmoodIdaho Falls$21K
- Douglas AndersenPocatello$7K
- Stephen DenagyAmmon$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.